Funding for this research was provided by:
The Ministry of Health, Labour, and Welfare of Japan
The Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (16K09834, 15K09246)
The Japanese Association for Complement Research
The Takeda Scientific Foundation
The Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development, AMED (17ek0109254h0001)
Text and Data Mining valid from 2018-03-06
Received: 1 November 2017
Accepted: 22 February 2018
First Online: 6 March 2018
Compliance with ethical standards
: Yoshihiro Fujimura is a recipient of patent royalty for ADAMTS13 activity-ELISA kits from Alfressa, Honoraria: Hideki Kato and Masaomi Nangaku from Alexion Pharma, Hideo Wada from IL Japan and Alexion Pharma, and Masanori Matsumoto from Asahi Kasei Pharma and Alexion Pharma, Research funding: Masanori Matsumoto from Bayer Yakuhin, Chugai Pharmaceutical, and Asahi Kasei Pharma, Subsidies or Donations: Masaomi Nangaku from Alexion Pharma.
: Ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number G10029) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.